Q-omics provides the consensus-scored CYP2F2P profile across patient tissues and cancer cell-line models. CYP2F2P expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CYP2F2P is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, CYP2F2P RNA expression shows 19,750 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, KIRP, and THYM as cancer lineages where CYP2F2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP2F2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP2F2P survival associations across molecular data types. CYP2F2P RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP2F2P RNA expression–survival associations across cancer types. High CYP2F2P expression shows unfavorable associations in ACC, LGG, UVM, BLCA and MESO, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CYP2F2P RNA expression.
This table summarizes CYP2F2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for CYP2F2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP2F2P shows lower tumor expression in KICH, LUSC, BRCA, BLCA and UCEC and higher tumor expression in KIRP. The KIRP box plot shows higher CYP2F2P RNA expression in tumor versus normal tissue (log2 FC = +0.578, t-test p < 0.001).
This table shows molecular features associated with CYP2F2P in patient tissues and cancer cell lines. In patient samples, CYP2F2P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
